Skip to main content
Premium Trial:

Request an Annual Quote

Sunbird Bio Completes Merger With Glympse Bio

NEW YORK – Singapore-based biotech firm Sunbird Bio said Wednesday that it has completed a merger with Cambridge, Massachusetts-based protein diagnostic company Glympse Bio.

The combined company, named Sunbird Bio, plans to develop protein-based diagnostics for conditions including neurological diseases and early-stage cancer.

The company has two main technology platforms, its APEX platform, which can identify aggregated amyloid-beta peptides in blood draws, enabling blood-based detection of Alzheimer's disease, and its Glympse platform, which measures dysregulated protease activity to detect disease, including early-stage cancer.

Sunbird said it is partnering with biopharma firms and researchers to bring to market tests for Alzheimer's and other neurological conditions on the APEX platform and to develop early-stage cancer diagnostics on the Glympse platform.

"I am excited about the synergies and opportunities created by the integration of our two innovative companies," John McDonough, executive chair and CEO of Sunbird Bio, said in a statement. "The APEX and Glympse platforms have the potential to dramatically improve standards of care for many diseases by overcoming the inaccessibility, invasiveness, and lack of reliability associated with current diagnostic approaches that limit their usefulness in drug development, disease detection, disease monitoring, and personalized treatment selection."

The newly combined company will have operational headquarters in Singapore and US headquarters in Cambridge.

Financial and other details of the merger were not disclosed.